OncoMatch/Clinical Trials/NCT03579875
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Is NCT03579875 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for fanconi anemia.
Treatment: Total Body Irradiation (TBI) (Plan 1) · Cyclophosphamide (CY) (Plan 1) · Fludarabine (FLU) · Methylprednisolone (MP) · Donor mobilized PBSC infusion · G-CSF · Cyclophosphamide (CY) (Plan 2) · Rituximab · Busulfan · Alemtuzumab · Melphalan · Rituximab — This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Lab requirements
Blood counts
hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)
Kidney function
serum creatinine < 1.8 mg/dl
Liver function
Adequate liver function (ALT < 2 x upper limit of normal)
Cardiac function
Adequate cardiac function
Adequate pulmonary, cardiac and liver function; Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin); Hepatic: ALT < 2 x upper limit of normal; Renal: serum creatinine < 1.8 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Masonic Cancer Center at University of Minnesota · Minneapolis, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify